Sofosbuvir/velpatasvir with or without low-dose ribavirin for patients with chronic hepatitis C virus infection and severe renal impairment - Liu, Chen-Hua; Chen, Chi-Yi; Su, Wei-Wen; Tseng, Kuo-Chih; Lo, Ching-Chu; Liu, Chun-Jen; Chen, Jyh-Jou; Peng, Cheng-Yuan; Shih, Yu-Lueng; Yang, Sheng-Shun; Huang, Chia-Sheng; Huang, Ke-Jhang; et al. (Gut, 2022)
Keywords: Adult; Adverse events; Aged; Aged, 80 and over; Alanine; Alanine transaminase; Antibodies; Antigens; Antiviral Agents - therapeutic use; Antiviral drugs; Architects; Bilirubin; Carbamates - therapeutic use; Chronic infection; chronic kidney disease; direct acting antiviral; Drug Combinations; Drug dosages; Drug Therapy, Combination; Female; Hemodialysis; Hepatitis B; Hepatitis C; hepatitis C virus; Hepatitis C, Chronic - complications; Hepatitis C, Chronic - drug therapy; Hepatology; Heterocyclic Compounds, 4 or More Rings - therapeutic use; Humans; Infections; Kidney diseases; Laboratories; Liver diseases; Male; Middle Aged; Nausea; Patients; Performance evaluation; Pharmacokinetics; Plasma; Pruritus; renal impairment; Renal Insufficiency, Chronic - classification; Renal Insufficiency, Chronic - complications; Retrospective Studies; Ribavirin; Ribavirin - therapeutic use; RNA polymerase; Sleep disorders; sofosbuvir; Sofosbuvir - therapeutic use; Sustained Virologic Response; Transplants & implants; velpatasvir; Young Adult; Abbott Park Illinois; United States--US; Germany; Taiwan; sofosbuvir; hepatitis C virus; chronic kidney disease; direct acting antiviral; velpatasvir; renal impairment